








# BEST OF ASCO 2025

## Summary

-  **Merck** mainly focused on KEYTRUDA (pembrolizumab) in endometrial cancer and classic Hodgkin lymphoma indication. The company presented data from KEYVIBE-005 and MK-4280-003 trials
-  **AstraZeneca** mainly focused on metastatic breast cancer and gastric cancer. Presented data from the DESTINY-Breast06, DESTINY-Breast09, ARTEMIDE- Gastric01, DESTINY-Gastric05 and DESTINY-Gastric04 trials
-  **BMS**, presented multiple sessions and poster, mainly focused on melanoma and NSCLC. Data from Checkmate 67T (nivolumab SC), Checkmate 77T, NADINA (nivolumab), RELATIVITY-047, J18119 (nivolumab + relatlimab) trials were presented
-  **Roche**, presented multiple sessions and poster mainly focusing on colon cancer, NSCLC, bladder and urinary tract cancer indications.
-  **Novartis**, presented multiple sessions and posters, focusing on breast cancer, chronic lymphocytic leukemia, melanoma, prostate cancer. Presented the data from NATALEE and trials
-  **Takeda**, mainly focused on ALUNBRIG (Brigatinib) and darolutamide in NSCLC and HNSCC
-  **Lilly** mainly focused on abemaciclib in breast cancer (TRADE and MONARCH E trials)

### Exhibitors/Sponsors



## Pembrolizumab

- 5-year follow-up results from the P3 **KEYNOTE-564** showed that, adjuvant pembro continued to demonstrate improved DFS and OS vs placebo in participants with ccRCC
- **KEYNOTE-522** study data showed that 16% of patients had an EFS in the KEYTRUDA + CT group vs. 24% of patients in the placebo + CT group in TNBC patients
- Long-term results of the randomized P3 **KEYNOTE-412** trial of pembro or placebo + concurrent CRT for unresected, locally advanced HNSCC
- An exploratory analysis of the P3 **KEYNOTE-689** trial (Neoadjuvant and adjuvant pembro + SOC) in LA HNSCC
- ORR data was superior in pembrolizumab + vibostolimab (anti-TIGIT) co-formulation arm vs. KEYTRUDA, in P2 (**KEYVIBE-005**) cohort B1 trial in 1L advanced dMMR endometrial cancer

## Trastuzumab deruxtecan (T-DXd)

- T-DXd + Pertuzumab demonstrated a statistically significant and clinically meaningful PFS benefit vs. THP in the **DESTINY-Breast 09** study; may represent a new first-line of SOC for patients with HER2+ mBC
- **DESTINY-Breast06** study established T-DXd as a new effective treatment option for patients with HR+, HER2-low and HER2-ultralow mBC, following  $\geq 1$  endocrine-based therapy
- Primary analysis of P3 (**DESTINY-Gastric04**) trial of T-DXd vs ramucirumab + paclitaxel in 2L HER2+ unresectable/metastatic GC or GEJA
- EFS analysis from the **MATTERHORN** study demonstrated, EFS to generally favour the durvalumab vs. placebo group across clinically relevant subgroups

## Ribociclib

- Dose reduction did not impact efficacy in the NATALEE study, iDFS was similar irrespective of the RDI of ribociclib
- Subgroup analysis of patients with or without liver metastases from RIGHT Choice, 1L ribociclib + endocrine therapy vs. combination CT in clinically aggressive HR+/HER2 advanced breast cancer

## Abemaciclib

- Ph2 TRADE trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer
- Impact of BMI on efficacy and safety of abemaciclin in breast cancer patients treated in MONARCHE trial

## Nivolumab

- Updated survival and biomarker analyses from **Checkmate 77T** of perioperative nivolumab vs placebo in patients with resectable NSCLC
- Safety and patient-reported outcomes of Phase 3 (CheckMate 67T) trial of nivolumab SC vs nivolumab IV in patients with previously treated advanced or metastatic ccRCC
- Final analysis from the **Checkmate 577** trial demonstrated sustained benefits in DFS and DMFS with adjuvant nivolumab vs placebo in patients with EC/GEJC following adjuvant CRT
- Data from the final analysis of the P3 **Checkmate 214** trial of NIVO + IPI continued to demonstrate improved survival with complete and durable response benefits compared with SUN in 1L aRCC
- OS with neoadjuvant nivolumab + CT in patients with resectable NSCLC in **CheckMate 816** trial

## Brigatinib

- Results of Ph2 (DISCOVERY) trial including Darolutamide + goserelin for androgen receptor-positive salivary gland cancers
- Preoperative brigatinib in resectable ALK+ NSCLC (WILDERNESS trial)

## Atezolizumab/Pertuzumab + Trastuzumab

- Standard CT alone or combined with atezolizumab as adjuvant stage III dMMR colon cancer (ATOMIC trial)
- Ph2 study of atezolizumab with carboplatin + pemetrexed followed by maintenance atezolizumab with pemetrexed for elderly patients with advanced NSCLC
- Data from TAPUR study pertuzumab + trastuzumab in patients with bladder & ovarian cancer with ERBB2/3 alterations

## Key Sessions